# US 2023/0066347 A1 · Ketamine treatment for amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066347 A1
- Document ID: US20230066347A1
- Status: Published application
- Kind: A1
- Application number: 17/770,543
- Filed: 2021-05-14
- Published: 2023-03-02
- Earliest claimed: 2020-05-15
- Assignees: University of Kansas
- Applicants: University of Kansas
- Inventors: Richard BAROHN; John A. STANFORD; Matthew MACALUSO
- Web page: https://patentgrep.com/patent/US20230066347A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating amyotrophic lateral sclerosis (ALS) is provided to extend life expectancy in a subject. The method can include administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine. The extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine. The first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.

## Claims

### Claim 1

A method of treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising:
providing ketamine; and
administering the ketamine to a subject having ALS.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering the ketamine so that the subject has an improvement of a condition of ALS.

### Claim 3 (depends on 1)

The method of claim 1, wherein the improvement in the condition of ALS includes at least one of:
improvement in probability of survival;
improvement in rate of deterioration of body weight;
improvement in projected days of survival; or
improvement in days of life after 20% loss of body weight before death.

### Claim 4 (depends on 3)

The method of claim 3, comprising administering the ketamine so that the subject has an extended life expectancy.

### Claim 5 (depends on 4)

The method of claim 4, wherein the extended life expectancy is determined by a higher probability of survival compared to without being administered ketamine.

### Claim 6 (depends on 4)

The method of claim 4, wherein the extended life expectancy is determined by a higher probability of survival compared to another subject having ALS with a similar life expectancy that is not administered ketamine.

### Claim 7 (depends on 3)

The method of claim 3, comprising administering the ketamine so that the subject has slower rate of deterioration of body weight.

### Claim 8 (depends on 7)

The method of claim 7, wherein the slower rate is compared to a rate of deterioration of body weight of the subject prior to being administered ketamine.

### Claim 9 (depends on 3)

The method of claim 3, comprising administering the ketamine so that the subject has a higher number of projected days of survival.

### Claim 10 (depends on 9)

The method of claim 9, wherein the higher number of projected days of survival are compared to a number of projected days of survival for the subject prior to being administered ketamine.

### Claim 11 (depends on 3)

The method of claim 3, comprising administering the ketamine after the subject has lost 20% of body weight compared to an initial body weight so that the subject has an improvement in days of life until death.

### Claim 12 (depends on 11)

The method of claim 11, wherein the improvement in days of life increases latency between 20% loss of body weight and death.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is diagnosed with ALS.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject has symptoms of ALS.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject being administered ketamine has less than or about 80% body weight compared to an initial body weight.

### Claim 16 (depends on 1)

The method of claim 1, wherein the ketamine is administered in dosing from about 0.1 mg/kg to about 100 mg/kg.

### Claim 17 (depends on 16)

The method of claim 16, wherein the administering is an IV infusion.

### Claim 18 (depends on 16)

The method of claim 16, wherein the dosing is at most every other day.

### Claim 19 (depends on 16)

The method of claim 16, wherein the dosing includes dosing twice weekly for a first period of time and then once weekly for a second period of time.

### Claim 20

A method of treating amyotrophic lateral sclerosis (ALS) to extend life expectancy in a subject, the method comprising:
providing ketamine; and
administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine, wherein the extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine, wherein the first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.
